Investors today commonly associate the obesity market with three main players: Orexigen (NAS: OREX) , which is still developing its drugs Contrave and Empatic, VIVUS (NAS: VVUS) , which recently launched its therapeutic Qsymia, and ArenaPharmaceuticals (NAS: ARNA) , which gained FDA approval for Belviq back in June and is poised to launch the drug with its partner Eisai.
Interestingly, a recent study showed that one of Eisai's epilepsy drugs, called Zonegran, may also be a potential weight-loss medicine. In the following video, health-care analysts Max Macaluso and David Williamson analyze this story and identify some things Arena investors should watch in both the near and long term.
Arena's stock has gone up by more than 400% year to date, but investors need to keep up with industry dynamics to determine where the stock will go from here. While the future looks bright for this company, there are still plenty of obstacles ahead. In our premium research report on Arena Pharmaceuticals, senior biotech analyst Brian Orelli, Ph.D., walks investors through the opportunities and threats facing the company. Click here now to learn more.
The article Will Arena Compete With Its Partner? originally appeared on Fool.com.
Max Macaluso, Ph.D., David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.